Status:
COMPLETED
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
Lead Sponsor:
Imbria Pharmaceuticals, Inc.
Collaborating Sponsors:
University of Oxford
Conditions:
Type 2 Diabetes
Diabetic Cardiomyopathies
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes
- Elevated HbA1c
- Elevated BMI
- Preserved left ventricular ejection fraction
- Diagnosis of HFpEF (Stage 2 only)
Exclusion
- Uncontrolled hypertension
- Contraindication to magnetic resonance scanning
- More than mild to moderate valvular heart disease
- Atrial fibrillation
- History of sustained ventricular tachycardia or cardiac arrest
- Inability to exercise (Stage 2 only)
- Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
Key Trial Info
Start Date :
April 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 6 2024
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04826159
Start Date
April 21 2021
End Date
August 6 2024
Last Update
June 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford University Hospital
Oxford, United Kingdom, OX3 9DU